{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:25:00Z","timestamp":1787765100520,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To characterize hemi-retinal vein occlusion (HRVO) in patients presenting to a multi-tier ophthalmology hospital network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective, hospital-based study analyzed 2,834,616 new patients between August 2010 and June 2021. Patients with a clinical diagnosis of HRVO in at least one eye were included as cases. Data were collected using an electronic medical record system. Data were compared to the findings noted in branch RVO (BRVO) and central RVO (CRVO) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      HRVO constituted 0.9% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 191) of all the retinal vein occlusions (RVOs), with the mean age being 60.55 \u00b1 10.14 years. Most patients were male (125, 65.45%) with unilateral (92.67%) affliction. Majority presented during the sixth (31.41%) or seventh (32.46%) decade of life. Most patients reported mild (37.07%) or moderate (27.32%) visual impairment, with vision &lt; 20\/200 being less common in HRVO (25.8%) and BRVO (17.2%) compared to CRVO (44.1%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001). Glaucoma was diagnosed and treated in 49 (23.90%) eyes, which was much higher than CRVO (11.45%) and BRVO (5.04%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), though neovascular glaucoma was much less than CRVO (2.9% vs. 9.2%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0037). On follow-up, HRVO eyes (12.2%) had lesser vision loss compared to CRVO eyes (13.7%) (this difference does not look very significant to me), though BRVO had the least (9.1%) vision loss.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HRVO is a rare RVO, presenting more in males. It causes less-severe visual impairment compared to CRVO. Large majority of patients with HRVO do not have identifiable systemic risk factors other than age. Preexisting glaucoma was more associated with HRVO compared to other RVOs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1712_23","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:01:17Z","timestamp":1704708077000},"page":"890-895","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Hemi-retinal vein occlusion: Characterizing a rare retinal vasculopathy"],"prefix":"10.4103","volume":"72","author":[{"given":"Yogita","family":"Kadam","sequence":"first","affiliation":[{"name":"Department of EyeSmart EMR and AEye, Public Health, and Economics Research Center, Hyderabad, Telangana, India"},{"name":"Indian Health Outcomes, Public Health, and Economics Research Center, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Thaku","sequence":"additional","affiliation":[{"name":"Anant Bajaj Retina Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Vipin","family":"Das","sequence":"additional","affiliation":[{"name":"Department of EyeSmart EMR and AEye, Public Health, and Economics Research Center, Hyderabad, Telangana, India"},{"name":"Indian Health Outcomes, Public Health, and Economics Research Center, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Indian Health Outcomes, Public Health, and Economics Research Center, Hyderabad, Telangana, India"},{"name":"Anant Bajaj Retina Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisha","family":"Senthil","sequence":"additional","affiliation":[{"name":"VST Centre for Glaucoma Care, L V Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Takkar","sequence":"additional","affiliation":[{"name":"Indian Health Outcomes, Public Health, and Economics Research Center, Hyderabad, Telangana, India"},{"name":"Anant Bajaj Retina Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"R1-20260504","first-page":"1178","article-title":"Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: Data from the FRB! registry","volume":"106","author":"Hunt","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0161-6420(98)95012-6","article-title":"Risk factors for hemiretinal vein occlusion: Comparison with risk factors for central and branch retinal vein occlusion: The eye disease case-control study","volume":"105","author":"Sperduto","year":"1998","journal-title":"Ophthalmology"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000320009","article-title":"Retinal vein occlusions","volume":"46","author":"Buehl","year":"2010","journal-title":"Dev Ophthalmol"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0161-6420(89)32884-3","article-title":"Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions","volume":"96","author":"Appiah","year":"1989","journal-title":"Ophthalmology"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamaophthalmol.2017.1141","article-title":"Baseline Factors associated with 6-month visual acuity and retinal thickness outcomes in patients with macular edema secondary to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 study report 4","volume":"135","author":"Scott","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ophtha.2009.09.019","article-title":"Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion","volume":"117","author":"Prasad","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/IAE.0b013e3181aa8dfe","article-title":"Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion","volume":"29","author":"Gregori","year":"2009","journal-title":"Retina"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ajo.2023.01.004","article-title":"Predictors of as-needed ranibizumab injection frequency in patients with macular edema following retinal vein occlusion","volume":"249","author":"Yiu","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/IAE.0b013e3181bced68","article-title":"Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion","volume":"30","author":"Park","year":"2010","journal-title":"Retina"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ophtha.2023.05.023","article-title":"SCORE 2 Report 24: Nonlinear relationship of retinal thickness and visual acuity in central retinal and hemiretinal vein occlusion","volume":"130","author":"Scott","year":"2023","journal-title":"Ophthalmology"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaophthalmol.2023.1463","article-title":"Cost-utility comparison of bevacizumab and aflibercept in the treatment of central or hemiretinal vein occlusion in the SCORE2 trial","volume":"141","author":"Kymes","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.4103\/ijo.IJO_1330_22","article-title":"Long-term real-world outcomes in retinal vein occlusions: How close are we to the trials?","volume":"70","author":"Shah","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3928\/23258160-20210201-05","article-title":"Patterns and predictors of successful treatment discontinuation in retinal vein occlusions with macular edema in the real world","volume":"52","author":"Lo","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R15-20260504","first-page":"407","article-title":"Gonioscopic findings in patients with acute central\/hemicentral retinal vein occlusions","volume":"118","author":"C\u0103lug\u0103ru","year":"2014","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"R16-20260504","first-page":"98","article-title":"Analysis of visual prognosis and correlative factors in retinal vein occlusion","volume":"38","author":"Zhang","year":"2002","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bjophthalmol-2021-320482","article-title":"Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: Data from the Fight Retinal Blindness! Registry","volume":"107","author":"Hunt","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"100904.","DOI":"10.1016\/j.ajoc.2020.100904","article-title":"\u201cGlaucomatous fields\u201d after monthly intravitreal injections: Normal tension glaucoma or a mimicker?","volume":"20","author":"Shah","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/eop.11.59","article-title":"Management of macular edema secondary to retinal vein occlusions","volume":"6","author":"Ciardella","year":"2011","journal-title":"Exp Rev Ophthalmol"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study Report 6","volume":"127","author":"Scott","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown DM; Campochiaro PA; Bhisitkul RB; Ho AC; Gray S; Saroj","year":"2011","journal-title":"Ophthalmology"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"396400.","DOI":"10.4103\/0301-4738.100533","article-title":"Integrated model of primary and secondary eye care for underserved rural areas: The L V Prasad Eye Institute experience","volume":"60","author":"Rao","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/jth.12982","article-title":"Prevalence and risk factors of retinal vein occlusion: The Gutenberg Health Study","volume":"13","author":"Ponto","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R26-20260504","first-page":"30","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion","volume":"196","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0161-6420(98)95012-6","article-title":"Risk factors for hemiretinal vein occlusion: Comparison with risk factors for central and branch retinal vein occlusion: The eye disease case-control study","volume":"105","author":"Sperduto","year":"1998","journal-title":"Ophthalmology"},{"key":"R28-20260504","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: Review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye (Lond)"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"e0220880.","DOI":"10.1371\/journal.pone.0220880","article-title":"Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion","volume":"14","author":"Cho","year":"2019","journal-title":"PLoS One"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000431196","article-title":"Neovascular glaucoma","volume":"55","author":"Havens","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"R31-20260504","first-page":"2617.","article-title":"Prevalence of glaucoma in retinal vein occlusion","volume":"57","author":"Ozaki","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-20260504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.oret.2021.03.009","article-title":"Hypercoagulability testing and hypercoagulable disorders in young central retinal vein occlusion patients","volume":"6","author":"Tauqeer","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R33-20260504","first-page":"1329.","article-title":"Systemic and ocular comorbidities in central retinal vein occlusion patients older and younger than 40 years old","volume":"61","author":"Chen","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R34-20260504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3341\/kjo.2005.19.1.34","article-title":"Neovascularization in branch retinal vein occlusion combined with arterial insufficiency","volume":"19","author":"Lee","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"R35-20260504","doi-asserted-by":"crossref","first-page":"14.","DOI":"10.1186\/s12886-016-0190-8","article-title":"Neovascular glaucoma: A retrospective review from a tertiary center in China","volume":"16","author":"Liao","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"R36-20260504","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.oret.2022.02.004","article-title":"Hemi- and central retinal vein occlusion associated with COVID-19 infection in young patients without known risk factors","volume":"6","author":"Ashkenazy","year":"2022","journal-title":"Ophthalmol Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1712_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:00:20Z","timestamp":1787763620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1712_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1712_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"2023-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}